Grundlæggende statistik
| CIK | 1445815 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bioxytran, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| April 15, 2026 |
Exhibit 3.9 |
|
| April 15, 2026 |
INSTRUCTIONS ON COMPLETING THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT Exhibit 10.92 INSTRUCTIONS ON COMPLETING THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT 1. The Company will comply with blue-sky laws in any state where an investment is consumed. You must submit proof of residency by attaching a legible copy of your driver’s license, passport or other government-issued photo identification. If the shares are to be issued in more than one name, both persons must su |
|
| April 15, 2026 |
Exhibit 10.91 COMMON SHARE WARRANT For the Purchase of () shares of Common Stock of Bioxytran, Inc. (the “Shares”) 1. Warrant Shares. THIS CERTIFIES THAT, for value received, , or its assigns (“Holder”), as registered owner of this Warrant Shares, issued by Bioxytran, Inc. (the “Company”), Holder is entitled, at any time or from time to time from , 2026 (the “Commencement Date”), and at or before |
|
| April 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K For the Transition Pe |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2026 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) |
|
| March 20, 2026 |
Exhibit 99.1 Bioxytran, Inc. Completes $1.2 Million Private Placement Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA – March 20, 2026 – Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on |
|
| March 13, 2026 |
Exhibit 3.1 |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2026 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) |
|
| March 2, 2026 |
EXHIBIT 99.1 Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 Randomized, Double-Blind, Placebo-Controlled Study Demonstrates 90% Day-5 Viral Clearance and Favorable Safety at Highest Dose compared to 20% placebo control BOSTON, MA — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company de |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2026 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) F |
|
| February 17, 2026 |
Exhibit 10.90 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE INDICATED BY [***]. DISTRIBUTION AGREEMENT Between Bioxytran, Inc., 75 2nd Ave., Ste 605, Needham, MA 02494, USA, including any successor(s) or assignee(s) (“BIXT”) And Khoury Me |
|
| February 17, 2026 |
Exhibit 99.1 Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR® Dietary Supplement Needham, MA — February 17, 2026 — Bioxytran, Inc. (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2026 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2025 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2025 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporati |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K For the Transition Pe |
|
| February 18, 2025 |
Bioxytran, Inc. 18,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-284415 Prospectus Bioxytran, Inc. 18,000,000 Shares of Common Stock This Prospectus relates to the resale by the investors listed in the section of this Prospectus entitled “Selling Stockholder” (the “Selling Stockholder”) of up to 18,000,000 shares (the “Shares”) of our Common Stock, par value $0.001 per share (“Common Stock”). The Shares cons |
|
| February 12, 2025 |
Bioxytran, Inc. 75 2nd Avenue, Suite 605 Needham, MA 02494 Bioxytran, Inc. 75 2nd Avenue, Suite 605 Needham, MA 02494 February 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Bioxytran, Inc. (CIK 0001445815) Registration Statement on Form S-1 File No. 333-284415 Amended Request for Acceleration of Effective Date Dear Sir or Ma |
|
| February 12, 2025 |
Bioxytran, Inc. 75 2nd Avenue, Suite 605 Needham, MA 02494 Bioxytran, Inc. 75 2nd Avenue, Suite 605 Needham, MA 02494 February 11, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Bioxytran, Inc. (CIK 0001445815) Registration Statement on Form S-1 File No. 333-284415 Request for Acceleration of Effective Date Dear Sir or Madam: Pur |
|
| February 12, 2025 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| February 5, 2025 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| February 5, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholder in private placement (3) 18,000,000 $ 0. |
|
| February 4, 2025 |
February 4, 2025 David Platt President and Chief Executive Officer Bioxytran, Inc. |
|
| January 23, 2025 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 January 23, 2025 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 January 23, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-284415 Delaying Amendment. Ladies and Gentlemen: Bioxytran, Inc. (the “Registrant”) hereby respectfully submits this Delay |
|
| January 22, 2025 |
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development Exhibit 99.1 Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development - Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, January 22, 2025 — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous |
|
| January 22, 2025 |
Amendment to Debt Modification Agreement dated December 30, 2024. Exhibit 10.89 Amendment to Debt Modification Agreement This AMENDMEND TO DEBT MODIFICATION AGREEMENT (this “Amendment #2’) is entered into as of December 27, 2024 (the “Amendment #2 Date”), by and between, Bioxytran, Inc., a Nevada corporation (the “Company”) and Walleye Opportunities Master Fund Ltd (“Purchaser”), each a “Party” and collectively the “Parties”, upon the following premises: WHEREAS |
|
| January 22, 2025 |
Amendment to Debt Modification Agreement dated July 25, 2024. Exhibit 10.87 Amendment to Debt Modification Agreement This AMENDMEND TO DEBT MODIFICATION AGREEMENT (this “Amendment’) is entered into as of July 25, 2024 (the “Amendment Date”), by and between, Bioxytran, Inc., a Nevada corporation (the “Company”) and Walleye Opportunities Master Fund Ltd (“Purchaser”), each a “Party” and collectively the “Parties”, upon the following premises: WHEREAS, On May 3 |
|
| January 22, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholder in private placement (3) 18,000,000 $ 0. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 15, 2025 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation |
|
| January 22, 2025 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| January 22, 2025 |
Closing Agreement with TRITON FUNDS LP, dated January 15, 2025. Exhibit 10.88 CLOSING AGREEMENT This Closing Agreement (the “Agreement”), dated as of January 15, 2025 (the “Issue Date”), is entered into between Bioxytran, Inc. a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor” and, together with the Company, the “Parties” and, each, individually, a “Party”). RECITALS: WHEREAS, upon the terms and subject to |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation |
|
| January 10, 2025 |
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs Exhibit 99.1 Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs BOSTON, MASSACHUSETTS, January 10, 2025 — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer’s disease, announced its preprint article titled “Immune Checkpoint Inhi |
|
| January 10, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2025 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation |
|
| October 29, 2024 |
Stock Sale and Purchase Agreement of NDPD Pharma, dated October 25, 2024 Exhibit 10.85 STOCK SALE AND PURCHASE AGREEMENT THIS STOCK SALE AND PURCHASE AGREEMENT (this “Agreement”) is dated as of October 25, 2024, and is made and entered into by and among Bioxytran, Inc., a Nevada corporation (“Buyer”) and the shareholders of NDPD Pharma, Inc. (“Sellers”) with respect to the following facts: A. WHEREAS, Sellers collectively own 15,000,000 shares of common stock (the “Sha |
|
| October 29, 2024 |
Extract from Valuation Report of NDPD Pharma, dated October 1, 2024 Exhibit 10.86 EXTRACT FROM VALUATION REPORT October 7, 2024 Ola Soderquist Chief Financial Officer BioXyTran, Inc. 72 2nd Avenue, Ste 605 Needham, MA 02494 Dear Mr.Soderquist, Brookline Valuation Services, Inc. (“BVS”) has been engaged by NDPD Pharma Inc., a Delaware corporation, for estimating Fair Market Value of NDPD Pharma, Inc. by valuing the licensing agreement, dated May 2, 2021, between ND |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| August 20, 2024 |
Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) |
|
| August 20, 2024 |
Exhibit 99.1 Bioxytran Measures the Presence of Carbon Monoxide When BXT-25 Delivers Oxygen to the Brain British Journal Article Elucidates the Effects of Carbon Monoxide in Mitochondrial Activity BOSTON, MASSACHUSETTS, August 24, 2024 (EIN Presswire) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, oth |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| July 17, 2024 |
Joint Venture Agreement between Bioxytran, the Heme Foundation and NDPD Pharma, dated July 15, 2024 Exhibit 10.84 Confidential Term Sheet July 15, 2024 Partner #1: Bioxytran, Inc. (“BIXT” or the “Company”) Partner #2: The Heme Foundation (“Heme” or the “Investor”) Partner #3: NDPD Pharma, Inc. (“NDPD” or the “Manufacturer”), and/or its assigns as designated by NDPD. Investment: The terms set forth below are indicative only and subject to review and acceptance of the Company and the Investor. Joi |
|
| July 17, 2024 |
Exhibit 99.1 Bioxytran Launches Joint Venture with the Heme Foundation for Development of a Universal Oxygen Carrier The Heme Foundation and Bioxytran join forces to address the global blood supply shortage with a blood substitute BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) - BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intrave |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) F |
|
| July 8, 2024 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 July 8, 2024 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 July 8, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-274576 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Ac |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) Fi |
|
| July 5, 2024 |
Exhibit 99.1 Bioxytran’s BXT-25 Drug Acts as a Universal Oxygen Carrier Like Hyperbaric Oxygenation for Stroke & Alzheimer’s Patients BXT-25 is expected to oxygenate the brain and be monitored by Bioxytran’s FDA approved medical device to trace all oxygen molecules BOSTON, MASSACHUSETTS, July 2, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology c |
|
| May 9, 2024 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File Num |
|
| May 9, 2024 |
Dismissal Consent from BF Borgers CPA PC, dated May 8, 2024 Exhibit 16.2 5400 W Cedar Ave Lakewood, CO 80226 Telephone: 303.953.1454 Fax: 303.945.7991 May 8, 2024 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Re: BioXyTran, Inc. Ladies and Gentleman: We have read the statements under item 4.01 in the Form 8-K dated May 8, 2024, of BioXyTran, Inc. (the “Company”) to be filed with th |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BI |
|
| April 19, 2024 |
Exhibit 10.83 THIS OPTION AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REG |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| April 19, 2024 |
Certificate of Designation of Convertible Preferred Stock, dated April 19, 2024 Exhibit 4.8 CERTIFICATE OF DESIGNATION of CONVERTIBLE PREFERRED STOCK of BIOXYTRAN, INC. (Pursuant to NRS 78.1955) Bioxytran, Inc., a corporation organized and existing under the Nevada Revised Statutes (hereinafter called the “Company”), hereby certifies that the following resolution was adopted by the Board of Directors of the Company as required by NRS 78.1955 at a meeting duly called and held |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2024 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) |
|
| March 22, 2024 |
Exhibit 10.81 THIS NOTE AND THE SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| March 22, 2024 |
Securities Purchase Agreement between Bioxytran, Inc. and Lender, dated March 15, 2024 Exhibit 10.82 SECURITY PURCHASE AGREEMENT This SECURITY PURCHASE AGREEMENT (this “Agreement”) is dated as of March 15, 2024 and is made by and between Bioxytran, Inc., a Nevada corporation (the “Company”), and the investors named on the signature pages hereto (the “Investors”). WHEREAS, the Company has offered to certain accredited investors (as defined in Regulation D under the Securities Act of |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| November 3, 2023 |
Form of Option Agreement dated June 4, 2021 Exhibit 10.80 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| October 2, 2023 |
Bioxytran, Inc. 18,578,982 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-272691 Prospectus Bioxytran, Inc. 18,578,982 Shares of Common Stock This Prospectus relates to the resale by the investors listed in the section of this Prospectus entitled “Selling Stockholders” (the “Selling Stockholders”) of up to 18,578,982 shares (the “Shares”) of our Common Stock, par value $0.001 per share (“Common Stock”). The Shares co |
|
| September 28, 2023 |
September 28, 2023 Attn: Jason Drory United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D. |
|
| September 26, 2023 |
United States securities and exchange commission logo September 26, 2023 David Platt, Ph. |
|
| September 26, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| September 26, 2023 |
Consent of Pinnacle Accountancy Group of Utah, PLLC, independent registered public accounting firm Exhibit 23.1.2 CONSENT OF PINNACLE ACCOUNTANCY GROUP OF UTAH, PLLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To Whom It May Concern: We hereby consent to the use in the amended Registration Statement on Form S-1 of BioXytran Inc., that was filed on or about September 22, 2023, of our Report of Independent Registered Public Accounting Firm, dated April 11, 2022, on the Consolidated Balance She |
|
| September 26, 2023 |
Consent of BF Borgers CPA PC, independent registered public accounting firm Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Registration Statement on Form S-1 of our report dated March 31, 2023 relating to the financial statements of Bioxytran, Inc. as of December 31, 2022 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO September 24, |
|
| September 21, 2023 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 21, 2023 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 21, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-274576 Delaying Amendment. Ladies and Gentlemen: Bioxytran, Inc. (the “Registrant”) hereby respectfully submits this cor |
|
| September 20, 2023 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 20, 2023 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 20, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-274576 Delaying Amendment. Ladies and Gentlemen: Bioxytran, Inc. (the “Registrant”) hereby respectfully submits this cor |
|
| September 19, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholders in private placement (3) 11,000,000 $ 0. |
|
| September 19, 2023 |
Debt Modification Agreement with Note Holder, dated May 5, 2023 Exhibit 10.78 DEBT MODIFICATION AGREEMENT THIS DEBT MODIFICATION AGREEMENT (this “Agreement”) is entered into as of May 5, 2022, by and among, Bioxytran, Inc., a Nevada corporation (the “Company”) and Walleye Opportunities Master Fund Ltd (“Purchaser”), each a “Party” and collectively the “Parties”, upon the following premises: WHEREAS, On May 3, 2021, Company sold and issued to Robert Salna (“Sal |
|
| September 19, 2023 |
Form of Closing Agreement with TRITON FUNDS LP, dated September 18, 2023 Exhibit 10.79 CLOSING AGREEMENT This Closing Agreement (the “Agreement”), dated as of September 18, 2023 (the “Issue Date”), is entered into between Bioxytran, Inc. a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). RECITALS: WHEREAS, upon the terms and subject to the conditions contained herein, the Investor shall purchase One Million Six H |
|
| September 19, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| August 24, 2023 |
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials Exhibit 99.1 Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials ● First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, August 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its Inv |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File |
|
| August 15, 2023 |
Prospectus Bioxytran, Inc. 2,504,903 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-272691 Prospectus Bioxytran, Inc. 2,504,903 Shares of Common Stock This Prospectus relates to the resale by the investors listed in the section of this Prospectus entitled “Selling Stockholders” (the “Selling Stockholders”) of up to 2,504,903 shares (the “Shares”) of our Common Stock, par value $0.001 per share (“Common Stock”). The Shares cons |
|
| August 10, 2023 |
August 10, 2023 Attn: Tyler Howes United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D. |
|
| August 9, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholders in private placement (3) 1,612,903 $ 0. |
|
| August 9, 2023 |
Consent of BF Borgers CPA PC, independent registered public accounting firm Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Registration Statement on Form S-1 of our report dated March 31, 2023 relating to the financial statements of Bioxytran, Inc. as of December 31, 2022 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO August 7, 2023 |
|
| August 9, 2023 |
Consent of Pinnacle Accountancy Group of Utah, PLLC, independent registered public accounting firm Exhibit 23.1.2 CONSENT OF PINNACLE ACCOUNTANCY GROUP OF UTAH, PLLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To Whom It May Concern: We hereby consent to the use in the amended Registration Statement on Form S-1/A of BioXytran Inc., that was filed on or about August 7, 2023, of our Report of Independent Registered Public Accounting Firm, dated April 11, 2022, on the Consolidated Balance Sheet |
|
| August 9, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| August 3, 2023 |
CALCULATION OF REGISTRATION FEE Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholders in private placement (3) 1,612,903 $ 0. |
|
| August 3, 2023 |
Amendment to Closing Agreement with TRITON FUNDS LP, dated August 2, 2023 EXHIBIT 10.77 AMENDED CLOSING AGREEMENT This Amended Closing Agreement (the “Agreement”), dated as of August 1, 2023 (the “Issue Date”), is entered into between Bioxytran, Inc. a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). RECITALS: WHEREAS, upon the terms and subject to the conditions contained herein, the Investor shall purchase Three |
|
| August 3, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| July 13, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| July 12, 2023 |
United States securities and exchange commission logo July 12, 2023 David Platt, Ph. |
|
| July 7, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| July 6, 2023 |
United States securities and exchange commission logo July 6, 2023 David Platt, Ph. |
|
| June 30, 2023 |
Consent of Pinnacle Accountancy Group of Utah, PLLC, independent registered public accounting firm Exhibit 23.1.2 CONSENT OF PINNACLE ACCOUNTANCY GROUP OF UTAH, PLLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To Whom It May Concern: We hereby consent to the use in the amended Registration Statement on Form S-1 of BioXytran Inc., that was filed on or about June 15, 2023, of our Report of Independent Registered Public Accounting Firm, dated April 11, 2022, on the Consolidated Balance Sheets o |
|
| June 30, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholders in private placement (3) 1,612,903 $ 0. |
|
| June 30, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| June 30, 2023 |
Consent of BF Borgers CPA PC, independent registered public accounting firm Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Registration Statement on Form S-1 of our report dated March 31, 2023 relating to the financial statements of Bioxytran, Inc. as of December 31, 2022 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO June 16, 2023 |
|
| June 29, 2023 |
United States securities and exchange commission logo June 29, 2023 David Platt, Ph. |
|
| June 16, 2023 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Security Being Registered Amount to be Registered Proposed Maximum Offering Price (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Shares of Common Stock sold to selling stockholders in private placement (3) 1,612,903 $ 0. |
|
| June 16, 2023 |
Consent of Pinnacle Accountancy Group of Utah, PLLC, independent registered public accounting firm Exhibit 23.1.2 CONSENT OF PINNACLE ACCOUNTANCY GROUP OF UTAH, PLLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To Whom It May Concern: We hereby consent to the use in the amended Registration Statement on Form S-1 of BioXytran Inc., that was filed on or about June 15, 2023, of our Report of Independent Registered Public Accounting Firm, dated April 11, 2022, on the Consolidated Balance Sheets o |
|
| June 16, 2023 |
Consent of BF Borgers CPA PC, independent registered public accounting firm Exhibit 23.1.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Registration Statement on Form S-1 of our report dated March 31, 2023 relating to the financial statements of Bioxytran, Inc. as of December 31, 2022 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO June 16, 2023 |
|
| June 16, 2023 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| June 12, 2023 |
Amendment to engagement letter with WallachBeth Capital LLC, dated May 8, 2023 Exhibit 10.75 AMENDMENT TO ENGAGEMENT LETTER THIS AMENDMENT TO ENGAGEMENT LETTER (this “Amendment”) is dated May 8, 2023 and is made by and between BioXyTran Inc. (“BioXyTran”) has engaged WallachBeth Capital LLC (“WallachBeth” and, together with BioXyTran, the “Parties”). WITNESSETH: WHEREAS, BioXyTran and WallachBeth entered into an Engagement Letter as on July 29, 2022 (“Original Agreement”); a |
|
| June 12, 2023 |
Form of Closing Agreement with TRITON FUNDS LP, dated June 8, 2023 Exhibit 10.76 CLOSING AGREEMENT This Closing Agreement (the “Agreement”), dated as of June 6, 2023 (the “Issue Date”), is entered into between Bioxytran, Inc. a Nevada corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). RECITALS: WHEREAS, upon the terms and subject to the conditions contained herein, the Investor shall purchase Five Hundred Thousand D |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File Num |
|
| June 12, 2023 |
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment Exhibit 99.1 Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment - Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other vira |
|
| May 12, 2023 |
Form of Subscription Agreement Exhibit 10.74 THE OFFERING Terms of Offering: Issuer: Bioxytran, Inc. is a Nevada corporation that develops branded and generic drug products for the United States and international markets market. Securities Offered: The Company is offering up to 9,375,000 (the “Maximum Offering”) of the Company’s Common stock, par value $0.001 (the “Common Stock”), at $0.32 per share. The Shares are being offere |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| May 12, 2023 |
Form of Private Purchase Agreement Exhibit 10.73 CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM BIOXYTRAN, INC. Bioxytran, Inc., a Nevada corporation (the “Company”, “we” or “us”), is offering (the “Offering”) up to $3,000,000 (the “Maximum Offering”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at $0.32 per share (the “Offering Price”). The shares are being offered on a “best efforts” basis. There is no minimum |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| March 7, 2023 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| March 7, 2023 |
Exhibit 16.1 March 7, 2023 Securities and Exchange Commission (the “Commission”) 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the former independent registered public accounting firm for Bioxytran, Inc. (the “Company”). We have read the statements made by the Company, which were provided to us and which we understand will be filed with the Commission pursuant to Item 4.0 |
|
| March 2, 2023 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 March 2, 2023 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 March 2, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-264250 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities A |
|
| February 6, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| February 6, 2023 |
Bioxytran Receives Approval to Initiate Trials with ProLectin-I Exhibit 99.1 Bioxytran Receives Approval to Initiate Trials with ProLectin-I BOSTON, MASSACHUSETTS, February 6, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Cent |
|
| December 14, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| December 14, 2022 |
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization Exhibit 99.1 Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization BOSTON, MASSACHUSETTS, December 14, 2022 (GLOBENEWSWIRE) ? BIOXYTRAN, INC. (OTCQB: BIXT) (the ?Company?), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India Pr |
|
| December 14, 2022 |
Bioxytran, Inc. Corporate Presentation, dated December 14, 2022 Exhibit 99.2 |
|
| December 14, 2022 |
Certificate of Incorporation Foreign (India) Subsidiary Exhibit 21.5 |
|
| December 8, 2022 |
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients Exhibit 99.1 Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients BOSTON, MASSACHUSETTS, December 8, 2022 (GLOBE NEWSWIRE) ? BIOXYTRAN, INC. (BIXT), (the ?Company?), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced the receipt of an Investigational New Drug (IND) authorization letter from India?s Centr |
|
| December 8, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| November 16, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| November 16, 2022 |
Exhibit 99.1 Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001) Treated population experienced no viral rebounds within the 14-day observation |
|
| November 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| November 14, 2022 |
Modification/Amendment to Officers’ Employment Contract, dated October 28, 2022. Exhibit 10.56 Amendment to Employment Agreement As of the date of signature of this amendment, the paragraph in the original employment agreement Between the Company and the employee saying: 8) If your employment relationship with the Company is terminated without cause prior to October 31, 2022, then the Company shall pay you a lump sum of $100,000 in severance, such payment to be conditioned upo |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| September 23, 2022 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 22, 2022 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 22, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-257339 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securit |
|
| September 22, 2022 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 21, 2022 RW WD 1 formrw-wd.htm BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 September 21, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. – Registration Statement on Form S-1, Registration No. 333-257339 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as |
|
| August 17, 2022 |
Form of Subscription Agreement. Exhibit 10.72 THE OFFERING Terms of Offering: Issuer: Bioxytran, Inc. is a Nevada corporation that develops branded and generic drug products for the United States and international markets market. Securities Offered: The Company is offering up to 1,400,000 (the ?Maximum Offering?) of the Company?s common stock, par value $0.001 (the ?Common Stock?), at $0.428571 per share. The Shares are being of |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File |
|
| August 16, 2022 |
BIXT / Bioxytran, Inc. / Offer Binder Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 to Schedule 13D) Bioxytran Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09075D102 (Cusip Number) Ola Soderquist - CFO Bioxytran, Inc. 75 2nd Ave., Ste 605 Needham, MA, 02494 (617) 454-1199 (Name, Address and Telephone Number of Person |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| August 1, 2022 |
Exhibit 99.1 Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus ProLectin-M, a new class of antiviral drug BOSTON, MASSACHUSETTS, August 1, 2022 (NEWSWIRE) ? BIOXYTRAN, INC. (Symbol: BIXT) (the ?Company?), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the |
|
| August 1, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| June 10, 2022 |
Exhibit 10.69 PATENT COOPERATION TREATY WO 2022/099052 PCT/US2021/058310 From the INTERNATIONAL BUREAU PCT To: NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION MCDONALD, J. Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D?AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant?s or agent?s file refere |
|
| June 10, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 10, 2022 |
Official USPTO Notice of Publication under 12(A) for the Trademark ProLectin Exhibit 10.71 UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) Commissioner for Trademarks www.uspto.gov OFFICIAL USPTO NOTICE OF PUBLICATION UNDER 12(a) U.S. Application Serial No. 90888912 Mark: PROLECTIN International Class(es): 005 Owner: Pharmalectin, Inc. Docket/Reference No. 51577-T02001 Issue Date: June 8, 2022 Your mark is scheduled to publish in the Trademark Official Gazette (TMOG) on |
|
| June 10, 2022 |
Exhibit 10.70 WO 2022/099061 PCT/US2021/058321 PATENT COOPERATION TREATY From the INTERNATIONAL BUREAU PCT NOTIFICATION CONCERNING AVAILABILITY OF THE PUBLICATION OF THE INTERNATIONAL APPLICATION To: MCDONALD, J., Cooper Clark & Elbing LLP 101 Federal Street 15th Floor Boston, MA 02110 ETATS-UNIS D?AMERIQUE Date of mailing (day/month/year) 12 May 2022 (12.05.2022) Applicant?s or agent?s file refer |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| May 16, 2022 |
NT 10-Q 1 n2583-x43nt10q.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-35027 CUSIP NUMBER 09075D 102 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N- |
|
| April 12, 2022 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| April 12, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee Common Stock, par value $0. |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-35027 CUSIP NUMBER 09075D 102 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: Decemb |
|
| February 28, 2022 |
BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 February 25, 2022 BIOXYTRAN, INC. 75 2nd Ave., Ste 605 Needham, Massachusetts 02494 February 25, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Bioxytran, Inc. ? Registration Statement on Form S-1, Registration No. 333-257339 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ?Securiti |
|
| January 14, 2022 |
Exhibit 99.1 Copyright ? Bioxytran 2022. All rights. Version 2.01.01 MIKE SHEIKH | [email protected] | (509) - 991 - 0245 Corporate Overview Copyright ? Bioxytran 2022. All rights. Version 2.01.01 Forward Looking Statement This Descriptive Presentation (the ?Presentation") has been prepared by Bioxytran, Inc (the ?Company?) and recipients are not entitled to rely on the accuracy or comp |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File |
|
| January 14, 2022 |
Form of Convertible Note, dated January 5, 2021 Exhibit 10.67 THIS NOTE AND THE SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE |
|
| January 14, 2022 |
Form of Note Purchase Agreement, dated January 5, 2022 Exhibit 10.68 NOTE PURCHASE AGREEMENT This NOTE PURCHASE AGREEMENT (this ?Agreement?) is dated as of , 2021 and is made by and between Bioxytran, Inc., a Nevada corporation (the ?Company?), and the investors named on the signature pages hereto (the ?Investors?). WHEREAS, the Company has offered to certain accredited investors (as defined in Regulation D under the Securities Act of 1933, as amended |
|
| November 17, 2021 |
Certificate of Incorporation Foreign (BVI) Subsidiary Exhibit 21.4 |
|
| November 17, 2021 |
Form of Subsidiary Option dated June 4, 2021 Exhibit 10.64 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| November 17, 2021 |
Form of Warrant dated June 4, 2021 Exhibit 10.63 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| November 17, 2021 |
Form of Private Placement Memorandum dated February 26, 2021 Exhibit 10.65 CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM BIOXYTRAN, INC. Bioxytran, Inc., a Nevada corporation (the ?Company?, ?we? or ?us?), is offering (the ?Offering?) up to $1.2 million (the ?Maximum Offering?) of the Company?s convertible preferred stock, with par value of $0.001 and stated value of $1.00 (the ?Common Stock?) convertible into the Company?s Common Stock at the lower of (1) $0.2 |
|
| November 17, 2021 |
Form of Private Placement Memorandum dated September 17, 2021 Exhibit 10.66 CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM BIOXYTRAN, INC. Bioxytran, Inc., a Nevada corporation (the ?Company?, ?we? or ?us?), is offering (the ?Offering?) up to $1.0 million (the ?Maximum Offering?) of the Company?s convertible notes (the ?Convertible Notes?) convertible into the Company?s common stock, par value $0.001 (the ?Common Stock?), at the time of the Company?s initial publ |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-35027 CUSIP NUMBER 09075D 102 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: Septem |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| July 26, 2021 |
Bioxytran, Inc. 17,653,077 Shares of Common Stock 424B4 1 n2583-x12424b4.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration No. 333-257339 Prospectus Bioxytran, Inc. 17,653,077 Shares of Common Stock This prospectus relates to the registration and resale of up to 17,653,077 shares of our common stock, par value $0.001 per share, by the selling stockholders: Debtor Date of Issuance Principal Amount Interest Robert Salna 5/ |
|
| July 26, 2021 |
Bioxytran, Inc. 5,300,000 Shares of Common Stock 424B4 1 n2583-x11424b4.htm PROSPECTUS SUMMARY Filed Pursuant to Rule 424(b)(4) Registration No. 333-257339 Prospectus Bioxytran, Inc. 5,300,000 Shares of Common Stock This prospectus relates to the sale of up to 5,300,000 shares of our common stock, par value $0.001 per share, or the Common Stock, by the Company. The shares will be sold at the fixed price of $1.00 per share until the completio |
|
| July 22, 2021 |
July 22, 2021 Attn: Dillon Hagius United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Re: Bioxytran, Inc. |
|
| July 20, 2021 |
S-1/A 1 n2583-x8s1a.htm FORM S-1/A We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. As filed with the Securities and Exchange Commission on July 19, 2021 Registration No. 001-35027 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOXYTR |
|
| July 20, 2021 |
July 19, 2021 Attn: Dillon Hagius United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Re: Bioxytran, Inc. |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2021 BIOXYTRAN, INC. (Exact Name of Registrant as Specified in Charter) Nevada 001-35027 26-2797630 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) F |
|
| July 1, 2021 |
United States securities and exchange commission logo July 1, 2021 David Platt, PhD Chairman Bioxytran, Inc. |
|
| June 24, 2021 |
License Agreement between Pharmalectin, Inc. and NDPD Pharma, Inc. dated May 2, 2021 Exhibit 10.60 LICENSE AGREEMENT ? This License Agreement (?Agreement?) is made this day of April, 2021 (the ?Effective Date?), by and among Pharmalectin, Inc. (?Licensee?), a Delaware corporation, and NDPD Pharma, Inc. (?NDPD?), a Delaware corporation. ? RECITALS: ? A. David Platt (?Platt?) has contributed to NDPD the ?Hydrolyzed Galactomannan? (as defined below) and (as defined below) that has th |
|
| June 24, 2021 |
We are a reporting company under Section 13 of the Securities Exchange Act of 1934, as amended. |
|
| June 24, 2021 |
Exhibit 10.62 STOCK OPTION PLAN BIOXYTRAN, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Bioxytran, Inc. 2017 Employee, Director and Consultant Stock Plan, have the following meanings: (a) ?Administrator? means the Board, unless it has delegated power to act on its beh |
|
| June 24, 2021 |
Exhibit 10.61 STOCK OPTION PLAN BIOXYTRAN, INC. 2021 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Bioxytran, Inc. 2021 Employee, Director and Consultant Stock Plan, have the following meanings: (a) ?Administrator? means the Board, unless it has delegated power to act on its beh |
|
| June 24, 2021 |
License Agreement between Bioxytran, Inc. and Pharmalectin, Inc. dated May 5, 2020 Exhibit 10.59 LICENSE AGREEMENT ? This License Agreement (?Agreement?) is made this day of April, 2021 (the ?Effective Date?), by and among Pharmalectin, Inc. (?Licensee?), a Delaware corporation, and Bioxytran, Inc. (?BIXT?), a Nevada corporation. ? RECITALS: ? A. David Platt (?Platt?) has contributed to BIXT the ?Modified Pectin? (as defined below) and (as defined below) that has therapeutic use |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2021 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File Num |
|
| June 7, 2021 |
Form of Convertible Note Agreement between Note Holders and Bioxytran, Inc., dated May 2 and 3, 2021 Exhibit 10.58 THIS NOTE AND THE SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE |
|
| May 17, 2021 |
10-Q 1 sf0114h10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001 |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| April 9, 2021 |
Joint Venture Agreement between Bioxytran and Pharmalectin Partners, LLC, dated November 15, 2020. Exhibit 10.56 April 30, 2020 Dear Mr. Sheikh, Bioxytran, Inc. (together with any affiliates, the "Company") is pleased to confirm its offer to employ as Executive Vice President of Business Development reporting to the Board of Directors. As discussed, your official start date with the Company was effective April 30, 2020. This position will be unpaid until a later date determined by the Board of |
|
| April 9, 2021 |
Amendment to Subsidiary’s Certificate of Corporation, dated April 29, 2020 EX-21.3 4 sf0106hex21-3.htm EXHIBIT 21.3 Exhibit 21.3 57 |
|
| April 9, 2021 |
Form of Employment Agreement of Mike Sheikh, dated May 1, 2020 EX-10.57 3 sf0106hex10-57.htm EXHIBIT 10.57 Exhibit 10.57 Issuer: Bioxytran Inc. or SPV as designated (the “Company”) Investors: Black Diamond Financial Group LLC (“Black Diamond” or “BDFG”), and/or its assigns as designated by BDFG, (collectively, the “Investor” and, together with permitted assignees, the “Holders”). Investment: The terms set forth below are indicative only and subject to review |
|
| March 31, 2021 |
NT 10-K 1 sf0108hnt10k.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-35027 CUSIP NUMBER 09075D 102 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-S |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| August 10, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exac |
|
| June 15, 2020 |
Form of Employment Agreement between Bioxytran, Inc. and Michael Sheikh, dated May 1, 2018. EX-1 2 ex1.htm MAY 1, 2020 Exhibit 1 May 1, 2020 Mike Scheikh 1905 S. Audubon Ct. Spokane, WA 99224 Dear Mr. Sheikh, Bioxytran, Inc. (together with any affiliates, the “Company”) is pleased to confirm its offer to employ as Executive Vice President of Business Development reporting to the Board of Directors. As discussed, your official start date with the Company was effective May 1, 2020. This po |
|
| June 15, 2020 |
EX-2 3 ex2.htm Exhibit 2 IR/CONSULTING AGREEMENT THIS AGREEMENT (“the agreement”), is made and entered into as of the 15th day of, February 2019, by Watermark Group Inc. and between Resources Unlimited NW LLC. hereinafter (“RU” or “We”), maintaining his principal office at 1905 S. Audubon Ct. Spokane WA 99224, and BioxyTran Inc. hereinafter (“BIXT,” or “Company”) maintaining its principal offices |
|
| June 15, 2020 |
BIXT / Bioxytran, Inc. / Sheikh Michael - SCHEDULE 13D (SF) Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bioxytran, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09075D102 (CUSIP Number) Ola Soderquist 233 Needham St., Ste 300 Newton, MA 02464 617-494-1199 (Name, Address and Telephone Number of Person Authorize |
|
| June 15, 2020 |
Exhibit 3 IR/CONSULTING AGREEMENT THIS AGREEMENT (“the agreement”), is made and entered into as of the 22nd day of, April 2019, by Resources Unlimited NW LLC, hereinafter (“RU”), maintaining their principal office at 1905 S. |
|
| May 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exa |
|
| March 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 26-2797630 (State or other Jurisdiction of Incorporation) (IRS Employer Identificatio |
|
| March 30, 2020 |
Exhibit 99.1 DAVID PLATT [email protected] (617) - 510 - 2539 Presentation Trials for BIXT - 10 against COVID - 19 FORWARD LOOKING STATEMENT This report contains forward - looking statements concerning possible applications for marketing approval and other regulatory matters, clinical trials, additional information, business strategies, and plans for the development of BioXyTran™. These |
|
| March 26, 2020 |
Exhibit 10.55 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| March 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File |
|
| March 26, 2020 |
Exhibit 10.54 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 18, 2020, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buye |
|
| March 18, 2020 |
BIXT / Bioxytran, Inc. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. (Exact name of r |
|
| March 18, 2020 |
Exhibit 14.2 Insider Trading Compliance Manual Bioxytran, Inc. Adopted October , 2019 In order to take an active role in the prevention of insider trading violations by its officers, directors, employees, consultants, advisors and other related individuals, the Board of Directors (the “Board”) of Bioxytran, Inc., a Nevada corporation, (the “Company”) has adopted the policies and procedures describ |
|
| March 18, 2020 |
Exhibit 21.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of October 5, 2017, Bioxytran, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock. Description of Common Stock The following description of our Common Stock is a summary an |
|
| March 12, 2020 |
8-K 1 ea119528-8kbioxytraninc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2018 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or oth |
|
| March 12, 2020 |
EX-10.53 3 ea119528ex53bioxytraninc.htm AMENDMENT #1 TO SECURITIES PURCHASE AGREEMENT BETWEEN AUCTUS FUND LLC AND BIOXYTRAN, INC., DATED FEBRUARY 25, 2019 Exhibit 10.53 AMENDMENT #1 THIS AMENDMENT #1 (the “Amendment”) to the Warrant (as defined below), is entered into by and between Bioxytran, Inc., a Nevada corporation (the “Company”), and Auctus Fund, LLC, a Delaware limited liability company (t |
|
| March 12, 2020 |
EX-99.1 2 ea119536ex99-1bioxytran.htm BIOXYTRAN, INC. PRESENTATION, DATED MARCH 12, 2020 Exhibit 99.1 DAVID PLATT [email protected] (617) - 510 - 2539 FORWARD LOOKING STATEMENT This report contains forward - looking statements concerning, among other things, possible applications for marketing approval and other regulatory matters, clinical trials, plans for the development of BioXyTran |
|
| March 12, 2020 |
Exhibit 10.52 AMENDMENT #1 THIS AMENDMENT #1 (the “Amendment”) to the Warrant (as defined below), is entered into by and between Bioxytran, Inc., a Nevada corporation (the “Company”), and Auctus Fund, LLC, a Delaware limited liability company (the “Holder”) (collectively the “Parties”). BACKGROUND A. The Company and Holder entered into a securities purchase agreement on October 24, 2018 (the “SPA” |
|
| March 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission File |
|
| February 26, 2020 |
Warrant to Purchase 22,000 shares of Common Stock of Bioxytran. Exhibit 10.51 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| February 26, 2020 |
EX-10.47 2 f8k021820ex10-47bioxytran.htm SECURITIES PURCHASE AGREEMENT BETWEEN POWER UP LENDING GROUP LLC AND BIOXYTRAN, INC., DATED JANUARY 18, 2020 Exhibit 10.47 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 18, 2020, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the |
|
| February 26, 2020 |
EX-10.48 3 f8k021820ex10-48bioxytran.htm 8% CONVERTIBLE DEBENTURE OF BIOXYTRAN, INC. TO POWER UP LENDING GROUP LLC IN THE PRINCIPAL AMOUNT OF $56,600 DATED JANUARY 18, 2020 Exhibit 10.48 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR |
|
| February 26, 2020 |
EX-10.49 4 f8k021820ex10-49bioxytran.htm SECURITIES PURCHASE AGREEMENT BETWEEN CROWN BRIDGE PARTNERS, LLC AND BIOXYTRAN, INC., DATED OCTOBER 30, 2019 Exhibit 10.49 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 19, 2020, by and between BIOXYTRAN, INC., a Nevada corporation, with headquarters located at 233 Needham Street, Suite 300, Newton |
|
| February 26, 2020 |
EX-10.50 5 f8k021820ex10-50bioxytran.htm 4% CONVERTIBLE NOTE OF BIOXYTRAN, INC. TO CROWN BRIDGE PARTNERS, LLC IN THE PRINCIPAL AMOUNT OF $55,000 DATED OCTOBER 30, 2019 Exhibit 10.50 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLI |
|
| January 31, 2020 |
BioxyTran, Inc. Presentation, dated January 31, 2020. Exhibit 99.1 |
|
| January 31, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| January 15, 2020 |
Exhibit 10.45 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| January 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2020 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| January 15, 2020 |
Securities Purchase Agreement between EMA Financial LLC and Bioxytran, Inc., dated January 10, 2020. Exhibit 10.44 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 10, 2020, is entered into by and between Bioxytran, Inc., a Nevada corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Purchaser” or “Holder”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Sect |
|
| January 15, 2020 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. Exhibit 10.46 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| January 6, 2020 |
Exhibit 10.43 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| January 6, 2020 |
Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 30, 2019, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “B |
|
| January 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| December 11, 2019 |
Other Events, Financial Statements and Exhibits 8-K 1 f8k120619bioxytraninc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or othe |
|
| December 11, 2019 |
BioxyTran, Inc. Presentation, dated December 11, 2019. Exhibit 99.1 |
|
| November 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| November 25, 2019 |
EX-10.40 3 f8k112019ex10-40bioxytran.htm 4% CONVERTIBLE NOTE OF BIOXYTRAN, INC. TO FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC. IN THE PRINCIPAL AMOUNT OF $125,000 DATED NOVEMBER 20, 2019 Exhibit 10.40 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF A |
|
| November 25, 2019 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. EX-10.41 4 f8k112019ex10-41bioxytran.htm WARRANT TO PURCHASE 50,000 SHARES OF COMMON STOCK OF BIOXYTRAN Exhibit 10.41 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (T |
|
| November 25, 2019 |
EX-10.39 2 f8k112019ex10-39bioxytran.htm SECURITIES PURCHASE AGREEMENT BETWEEN FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC AND BIOXYTRAN, INC., DATED NOVEMBER 20, 2019 Exhibit 10.39 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 20, 2019, by and between BIOXYTRAN, INC, a Nevada corporation, with headquarters located at 233 Needham Street, Suit |
|
| November 13, 2019 |
BIXT / Bioxytran, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35027 BIOXYTRAN, INC. |
|
| November 12, 2019 |
8-K 1 f8k110719bioxytraninc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other |
|
| November 12, 2019 |
EX-10.36 3 f8k110719ex10-36bioxytran.htm FORM OF 4% CONVERTIBLE NOTE OF BIOXYTRAN, INC. TO GS CAPITAL PARTNERS, LLC. IN THE PRINCIPAL AMOUNT OF $125,000 DATED NOVEMBER 7, 2019 Exhibit 10.36 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE |
|
| November 12, 2019 |
Exhibit 10.35 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 7, 2019, by and between BIOXYTRAN, INC, a Nevada corporation, with headquarters located at 233 Needham Street, Suite 300, Newton, MA 02464 (the “Company”), and GS CAPITAL PARTNERS, LLC, a New York limited liability company, with its address at 30 Broad Street, Suite 1201, New York |
|
| November 12, 2019 |
Form of Letter Agreement between FON Consulting, LLC and Bioxytran, Inc. dated November 11, 2019. EX-10.38 5 f8k110719ex10-38bioxytran.htm FORM OF LETTER AGREEMENT BETWEEN FON CONSULTING, LLC AND BIOXYTRAN, INC. DATED NOVEMBER 11, 2019 Exhibit 10.38 11/11/2019 Bioxytran 233 Needham Street Suite 300 Newton, MA 02464 Dear David, As we discussed, I believe that FON Consulting LLC (“FON”) and Bioxytran, Inc. (the “Company”) can work together to make the pertinent introductions that you are looking |
|
| November 12, 2019 |
Form of Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. EX-10.37 4 f8k110719ex10-37bioxytran.htm FORM OF WARRANT TO PURCHASE 50,000 SHARES OF COMMON STOCK OF BIOXYTRAN Exhibit 10.37 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AM |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission F |
|
| November 5, 2019 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. EX-10.32 6 f8k102319a1ex10-32bioxytran.htm WARRANT TO PURCHASE 50,000 SHARES OF COMMON STOCK OF BIOXYTRAN. Exhibit 10.32 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 19 |
|
| November 5, 2019 |
Exhibit 10.34 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| November 5, 2019 |
Exhibit 10.31 Note: October 23, 2019 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STA |
|
| November 5, 2019 |
EX-10.29 3 f8k102319a1ex10-29bioxytran.htm CONVERTIBLE DEBENTURE OF BIOXYTRAN, INC. TO PEAK ONE OPPORTUNITY FUND, L.P. IN THE PRINCIPAL AMOUNT OF $120,000 DATED OCTOBER 22, 2019. Exhibit 10.29 SIGNING DEBENTURE NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF AN |
|
| November 5, 2019 |
Exhibit 10.28 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 22, 2019, is entered into by and between BIOXYTRAN, INC., a Nevada corporation, (the “Company”) and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (the “Buyer”). WITNESSETH: WHEREAS, the Company and the Buyer are executing and delivering this Agreement in accordanc |
|
| November 5, 2019 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. Exhibit 10.30 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| November 5, 2019 |
Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2019, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Bu |
|
| October 28, 2019 |
Exhibit 10.34 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| October 28, 2019 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. Exhibit 10.32 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| October 28, 2019 |
Exhibit 10.29 SIGNING DEBENTURE NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SECURITIES ARE RESTRICTED AND MAY NOT BE OFFERED, RESOLD, PLEDGED OR TRANSFERRED EXCEPT AS PERMITTED UNDER THE ACT PUR |
|
| October 28, 2019 |
Warrant to Purchase 50,000 shares of Common Stock of Bioxytran. Exhibit 10.30 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE R |
|
| October 28, 2019 |
Exhibit 10.28 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 22, 2019, is entered into by and between BIOXYTRAN, INC., a Nevada corporation, (the “Company”) and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (the “Buyer”). WITNESSETH: WHEREAS, the Company and the Buyer are executing and delivering this Agreement in accordanc |
|
| October 28, 2019 |
Exhibit 10.31 Note: October 23, 2019 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STA |
|
| October 28, 2019 |
Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2019, by and between BIOXYTRAN, INC., a Nevada corporation, with its address at 233 Needham St., Ste 300, Newton, MA 02464 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Bu |
|
| October 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| September 13, 2019 |
Exhibit 10.28 Advisory Board Agreement This Advisory Board Agreement (the “Agreement”), is entered into on September 13, 2019 by Bioxytran, Inc., with an address at 233 Needham Street, Suite 300, Newton MA, 02464 (the “Company”), and John Jensen (the “Advisor”) with an address c/o Westbury Group LLC at 39 Riverside Avenue, Westport, CT 06880 (the “Advisor”). In consideration of the representations |
|
| September 13, 2019 |
Exhibit 10.29 Advisory Board Agreement This Advisory Board Agreement (the “Agreement”), is entered into on September 13, 2019 by Bioxytran, Inc., with an address at 233 Needham Street, Suite 300, Newton MA, 02464 (the “Company”), and Patrick Huddie (the “Advisor”) with an address c/o Westbury Group LLC at 39 Riverside Avenue, Westport, CT 06880 (the “Advisor”). In consideration of the representati |
|
| September 13, 2019 |
Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 BIOXYTRAN, INC. (Exact Name if Business Issuer as specified in its Charter) Nevada 001-35027 26-2797630 (State or other Jurisdiction of Incorporation) (Commission F |
|
| September 13, 2019 |
Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board Exhibit 99.1 Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board BOSTON, MASSACHUSETTS, September 13, 2019 (GLOBE NEWSWIRE) - BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company, focused on delivering a small molecule carrying oxygen to the brains of stroke victims, announced today that it has invited John Jensen and Dr. Patrick Huddie from |
|
| August 9, 2019 |
BIXT / Bioxytran, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-214306 BIOXYTRAN, INC. (Exa |
|
| August 1, 2019 |
Exhibit 99.2 Bioxytran Inc. Appoints Cynthia Ekberg Tsai to Company Advisory Board BOSTON, MASSACHUSETTS, Aug. 01, 2019 (GLOBE NEWSWIRE) - BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims, announced today that it has appointed Cynthi |
|
| August 1, 2019 |
EX-99.1 4 f8k072619ex99-1bioxytran.htm PRESS RELEASE DATED JULY 26, 2019 Exhibit 99.1 Bioxytran Inc. Bolsters Advisory Board with Addition of Veteran Financial Advisor Jonathan Barkman BOSTON, MASSACHUSETTS, July 24, 2019 (GLOBE NEWSWIRE) - BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a |
|
| August 1, 2019 |
Form of Advisory Board Agreement between Bioxytran, Inc. and Cynthia Tsai effective July 16, 2019. Exhibit 10.27 Advisory Board Agreement This Advisory Board Agreement (the “Agreement”), dated as of July 16, 2019 (the “Effective Date”), and is entered into on July 26, 2019 by Bioxytran, Inc., with a business address at 233 Needham Street, Suite 300, Newton MA, 02464 and its successors and assigns (the “Company”), and Cynthia Tsai (the “Advisor”) with an address at (the “Advisor”). In considerat |
